The bar chart provides information about the proportion of the entire revenues of a pharmaceutical business, by area, over a period of 4 years, starting from 2002.
Overall, it is clear to see that while the rate of a drug business’s total income in Europe and America dwindled significantly, the opposite trend was seen in Asia. Notably, the total earnings of a pharmaceutical company in Asia were lowest at the start of the period but ranked first in the last year.
As can be seen from the chart, a drug enterprise’s general sales in America exhibited the highest proportion, comprising slightly more than two-fifths, while the figure for Asia was the lowest with a quarter in 2002. Two years later, the entire revenues of a pharmaceutical business in America bottomed out at 27% before increasing tediously to 30% in 2006. In terms of Asia, the proportion went up instantly by 12% from 2002 to 2005 and peaked at 40% in 2006.
The rate of the whole profits of a pharmaceutical business in Europe accounted for 34%, after that it witnessed mild growth in the next year. The figure touched the highest level of 38% in 2004, followed by a considerable fall to bottom out at a third in 2006.